To date, the only HIV vaccine trial showing the ability to reduce infection risk was the RV144 trial, which evaluated a regimen comprising a prime with canarypox vectored vaccine (ALVAC) expressing gag/pol/nef and boost with recombinant HIV gp120 [38]. Here, S100B is linked to infection.